Adoptive T cell therapy (ACT) in combination with lymphodepleting chemotherapy is an
effective strategy to induce the eradication of cancer, providing long-term regressions in
patients. However, only a minority of patients that receive ACT with tumor-specific T cells
exhibit durable benefit. Thus, there is an urgent need to characterize mechanisms of
resistance and define strategies to alleviate immunosuppression in the context of ACT in
cancer. This article reviews the importance of lymphodepleting regimens in promoting the …